Holen Sie sich die Stockscreener-App
67.47
0.15%
-0.10
Handel nachbörslich:
67.26
-0.21
-0.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$67.57
Offen:
$67.59
24-Stunden-Volumen:
2.69M
Relative Volume:
0.46
Marktkapitalisierung:
$26.31B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
47.23
EPS:
1.4285
Netto-Cashflow:
$570.80M
1W Leistung:
+0.06%
1M Leistung:
+6.30%
6M Leistung:
-21.85%
1J Leistung:
-15.91%
1-Tages-Spanne:
$67.12
$68.18
1-Wochen-Bereich:
$66.35
$68.18
52-Wochen-Spanne:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
67.47 | 26.35B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
124.57 | 217.08B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
95.76 | 142.40B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
352.50 | 135.46B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.15 | 123.74B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.94 | 50.40B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Dexcom Stock Finds Its Range: What The Latest Drift, Data, And Deals Signal For 2026 - AD HOC NEWS
FDA says Dexcom issues correction for Dexcom G6 and G6 Pro software - marketscreener.com
E. Ohman J or Asset Management AB Raises Position in DexCom, Inc. $DXCM - Defense World
SWS Partners Purchases 19,073 Shares of DexCom, Inc. $DXCM - MarketBeat
Beacon Investment Advisory Services Inc. Trims Stock Position in DexCom, Inc. $DXCM - Defense World
Class Action Alert: Levi & Korsinsky Reminds DexCom (DXCM) Investors of December 26, 2025 Deadline - ACCESS Newswire
DexCom, Inc. Sued for Securities Law Violations – Investors - GlobeNewswire
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before December 26, 2025 to Discuss Your RightsDXCM - Finviz
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, - GlobeNewswire
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm - GlobeNewswire Inc.
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Levi & Korsinsky Urges DexCom (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
December 26, 2025 Deadline: Join Class Action Lawsuit Against DexCom, Inc. (DXCM)Contact Levi & Korsinsky - ACCESS Newswire
Securities Lawsuit Alert: DexCom, Inc. (DXCM) InvestorsContact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
DAVENPORT & Co LLC Increases Position in DexCom, Inc. $DXCM - MarketBeat
Lost Money on DexCom, Inc. (DXCM)? Urged to Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - ACCESS Newswire
Investor Alert: Deadline Approaching to Join DexCom, Inc. (DXCM) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Class Action Lawsuit Filed: DexCom, Inc. (DXCM)Join by December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
Voya Investment Management LLC Sells 186,132,582 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom (DXCM): Reassessing Valuation After Class Action Lawsuits and New FDA Clearance for Smart Basal - Sahm
An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 47% Undervalued - 富途牛牛
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
DexCom, Inc. (DXCM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 26, 2025 Deadline - Stockhouse
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc.(DXCM) Shareholders - The Malaysian Reserve
Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained - ACCESS Newswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DexCom, Inc. $DXCM Shares Sold by Congress Asset Management Co. - MarketBeat
Dexcom G6 Continuous Glucose Monitoring (CGM) Lawsuit - Drugwatch.com
Class Action Filed Against DexCom, Inc. (DXCM) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
DexCom, Inc. (DXCM) Announces Leadership Transition with New CEO Appointment - GuruFocus
Dexcom Names Jacob Leach as Incoming Chief Executive - TipRanks
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Inc Announces CEO Appointment - TradingView — Track All Markets
Shareholders SueWallSt in New Class Action Against DexCom, Inc.Act Now - Nasdaq
2025-12-22 | Lost Money on DexCom, Inc. (DXCM)? Urged to Join Class Action Before December 26, 2025Contact Levi & Korsinsky | NDAQ:DXCM | Press Release - Stockhouse
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential - Insider Monkey
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
10 Best Growth Stocks to Buy in 2026 - Insider Monkey
What sentiment indicators say about DexCom Inc. stockQuarterly Profit Review & AI Enhanced Trading Signals - Улправда
December 26, 2025 Deadline Approaching: Join Class Action Against DexCom, Inc. (DXCM)Contact Levi & Korsinsky - Stockhouse
Important December 26, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Investors of Securities Fraud Class Action Lawsuit - The Malaysian Reserve
Zevenbergen Capital Investments LLC Purchases 62,098 Shares of DexCom, Inc. $DXCM - MarketBeat
Is DexCom Inc. stock supported by strong cash flowsJuly 2025 Trends & Smart Money Movement Tracker - Улправда
Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations - Nasdaq
Will DexCom Inc. stock sustain high P E ratios2025 Key Lessons & Reliable Entry Point Trade Alerts - Улправда
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.55%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):